InSilicoTrials, Axoltis Pharma Announce Neurological Therapy Collaboration
Partnership intended to enhance development plan of biopharma’s drug candidate.
InSilicoTrials, an artificial intelligence (AI) and simulation tools provider for drug development, and Axoltis, a biopharma company, have announced a partnership focused on optimizing the clinical development plan of Axoltis' drug candidate, NX210c. By implementing the InSilicoNeuro suite, which includes a variation of CNS models, the organizations will assess the impact of Axoltis' drug candidate on virtual patients with different conditions, including Amyotrophic Lateral Sclerosis (ALS), Parkinson's Disease and Multiple sclerosis (MS).
"We are thrilled to collaborate with Axoltis in our shared mission to advance therapeutic solutions for neurological disorders," said Luca Emili, CEO of InSilicoTrials. "This partnership represents an exciting synergy between cutting-edge simulation technologies and innovative biotechnological advancements. Together, we aim to unlock new insights and develop groundbreaking treatments that will positively impact the lives of patients with neurologic impairments worldwide."
Reference: InSilicoTrials and Axoltis Pharma Collaborate to Advance Therapeutic Solutions for Neurological Disorders. PR Newswire. July 27, 2023. Accessed July 28, 2023. https://www.prnewswire.com/news-releases/insilicotrials-and-axoltis-pharma-collaborate-to-advance-therapeutic-solutions-for-neurological-disorders-301886789.html
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
